These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 29330749)

  • 1. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
    Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
    Chauffert B; Feuvret L; Bonnetain F; Taillandier L; Frappaz D; Taillia H; Schott R; Honnorat J; Fabbro M; Tennevet I; Ghiringhelli F; Guillamo JS; Durando X; Castera D; Frenay M; Campello C; Dalban C; Skrzypski J; Chinot O
    Ann Oncol; 2014 Jul; 25(7):1442-1447. PubMed ID: 24723487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
    Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
    Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
    Tipping M; Eickhoff J; Ian Robins H
    J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
    Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
    J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
    J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
    Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
    J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
    Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
    J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.